Lactobacillus gasseri
Research reviewed: Up until 03/2026
Lactobacillus gasseri is a dietary supplement with 10 published peer-reviewed studies involving 918 participants, researched for Weight Management & Abdominal Fat Reduction, Gut Health & Digestive Function, Stress, Sleep & Metabolic Health.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Weight Management & Abdominal Fat Reduction
StrongGut Health & Digestive Function
ModerateStress, Sleep & Metabolic Health
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Weight Management & Abdominal Fat Reduction
To evaluate the effect of Lactobacillus gasseri SBT2055 on abdominal adiposity in adults with obese tendencies.
Study Type
Randomized, double-blind, placebo-controlled, multicenter trial
Purpose
To evaluate the effect of Lactobacillus gasseri SBT2055 on abdominal adiposity in adults with obese tendencies.
Dose
200 g/day fermented milk containing L. gasseri SBT2055 (~10^10 CFU/day)
Participants
87 adults with BMI 24.2-30.7 kg/m² (43 active, 44 control)
Duration
12 weeks
Results
Visceral fat decreased by 4.6% and subcutaneous abdominal fat by 3.3% (both p<0.01). Body weight dropped 1.4%, BMI fell 1.5%, waist circumference decreased 1.8%, and hip circumference reduced 1.5% (all p<0.001). Control group showed no significant changes.
How They Measured It
CT scan measurement of visceral and subcutaneous fat areas, body weight, BMI, waist and hip circumference
To evaluate the dose-dependent effect of L. gasseri SBT2055 on abdominal adiposity in adults with large visceral fat areas.
Study Type
Randomized, double-blind, parallel-group, multicenter trial
Purpose
To evaluate the dose-dependent effect of L. gasseri SBT2055 on abdominal adiposity in adults with large visceral fat areas.
Dose
200 g/day fermented milk with 10^7 CFU/g, 10^6 CFU/g, or 0 (control) of LG2055
Participants
210 healthy Japanese adults with large visceral fat areas (80.2-187.8 cm²)
Duration
12 weeks consumption + 4 weeks cessation
Results
Both treatment groups showed significant reductions in visceral fat: -8.5% in the high-dose group and -8.2% in the low-dose group. Benefits attenuated after 4 weeks of cessation, suggesting ongoing consumption is necessary.
How They Measured It
CT scan measurement of abdominal visceral and subcutaneous fat areas
To evaluate the effect of L. gasseri BNR17 on body weight and anthropometric measures in overweight and obese adults.
Study Type
Randomized, double-blind, placebo-controlled trial
Purpose
To evaluate the effect of L. gasseri BNR17 on body weight and anthropometric measures in overweight and obese adults.
Dose
10^10 CFU/day L. gasseri BNR17 (6 capsules daily, 2 before each meal)
Participants
62 obese volunteers aged 19-60 with BMI ≥23 kg/m² (57 completed)
Duration
12 weeks
Results
The probiotic group showed modest weight reduction (-1.1 +/- 2.2 kg) and decreased waist and hip circumferences more than placebo, but no statistically significant differences between groups emerged for most endpoints.
How They Measured It
Body weight, BMI, waist and hip circumference measurements at baseline and weeks 4, 8, and 12
To evaluate whether L. gasseri BNR17 supplementation reduces visceral fat accumulation and waist circumference in obese adults.
Study Type
Randomized, double-blind, placebo-controlled trial
Purpose
To evaluate whether L. gasseri BNR17 supplementation reduces visceral fat accumulation and waist circumference in obese adults.
Dose
Low-dose: 10^9 CFU/day; High-dose: 10^10 CFU/day
Participants
90 volunteers aged 20-75 years with BMI 25-35 kg/m²
Duration
12 weeks
Results
High-dose group showed significantly reduced visceral adipose tissue compared to placebo (p=0.038). Difference in VAT areas of the high-dose group compared with placebo was -21.6 cm² (p=0.012). Waist circumference decreased in both treatment groups.
How They Measured It
CT scan measurement of visceral adipose tissue, waist circumference, body weight, BMI
To evaluate the species-specific effects of Lactobacillus species on weight gain in humans and animals.
Study Type
Comparative meta-analysis
Purpose
To evaluate the species-specific effects of Lactobacillus species on weight gain in humans and animals.
Dose
Various (across included studies)
Participants
Meta-analysis of 17 human RCTs plus animal studies
Duration
Various
Results
L. gasseri was associated with weight loss both in obese humans and in animals. L. acidophilus was associated with weight gain. Effects were species- and strain-specific, with L. plantarum also associated with weight loss.
How They Measured It
Meta-analysis of 17 RCTs in humans, 51 farm animal studies, and 14 experimental models
Gut Health & Digestive Function
To evaluate whether L. gasseri SBT2055 promotes fecal fat excretion via modification of fat emulsion properties.
Study Type
Randomized, double-blind, placebo-controlled trial
Purpose
To evaluate whether L. gasseri SBT2055 promotes fecal fat excretion via modification of fat emulsion properties.
Dose
100 g/day fermented milk containing L. gasseri SBT2055
Participants
Healthy Japanese subjects
Duration
7 days
Results
Subjects consuming LG2055-containing fermented milk showed significantly increased fecal fat levels compared to baseline. The strain enlarged fat emulsion droplet size, suppressing lipase-mediated fat hydrolysis and promoting fecal fat excretion.
How They Measured It
Fecal fat content analysis, fat emulsion droplet size measurement
To evaluate the effect of L. gasseri OLL2716 pretreatment on first-line Helicobacter pylori eradication therapy.
Study Type
Randomized controlled trial
Purpose
To evaluate the effect of L. gasseri OLL2716 pretreatment on first-line Helicobacter pylori eradication therapy.
Dose
L. gasseri OLL2716-containing yogurt 112 g twice daily plus standard triple therapy
Participants
229 patients with H. pylori infection
Duration
4 weeks (3 weeks pretreatment + 1 week during triple therapy)
Results
Yogurt plus triple therapy achieved 82.6%/85.6% eradication rates vs 69.3%/74.5% for triple therapy alone (ITT/PP; p=0.018/0.041). Eradication of clarithromycin-resistant strains trended higher with combination therapy (38.5% vs 28.0%).
How They Measured It
H. pylori eradication rates (intention-to-treat and per-protocol analysis), clarithromycin susceptibility testing
To evaluate the effects of L. gasseri OLL2716 on H. pylori-associated dyspepsia symptoms.
Study Type
Multicenter, randomized, double-blind, placebo-controlled trial
Purpose
To evaluate the effects of L. gasseri OLL2716 on H. pylori-associated dyspepsia symptoms.
Dose
L. gasseri OLL2716-containing yogurt once daily
Participants
131 H. pylori-positive volunteers (mean age 48.9 years)
Duration
12 weeks
Results
Probiotic group showed significantly reduced postprandial fullness vs baseline, and fewer patients experienced bloating severity scores above 10 vs placebo. No significant differences in H. pylori detection or pepsinogen ratios.
How They Measured It
Dyspepsia symptom scores, H. pylori detection, serum pepsinogen ratios
Stress, Sleep & Metabolic Health
To evaluate the effects of paraprobiotic L. gasseri CP2305 on stress-related symptoms and sleep quality in medical students.
Study Type
Randomized controlled trial
Purpose
To evaluate the effects of paraprobiotic L. gasseri CP2305 on stress-related symptoms and sleep quality in medical students.
Dose
Daily paraprobiotic CP2305 supplementation
Participants
32 healthy medical students (21 males, 11 females)
Duration
5 weeks
Results
Sleep quality improved overall (p=0.038). Men showed shortened sleep latency (p=0.035) and increased duration (p=0.048). Diarrhea-like symptoms effectively controlled in men (p=0.005). Sex-related differences in effects were observed.
How They Measured It
Pittsburgh Sleep Quality Index (PSQI), sleep latency, gut microbiota analysis
To evaluate the health benefits of L. gasseri CP2305 tablets in young adults exposed to chronic stress.
Study Type
Randomized, double-blind, placebo-controlled trial
Purpose
To evaluate the health benefits of L. gasseri CP2305 tablets in young adults exposed to chronic stress.
Dose
CP2305-containing tablets once daily
Participants
60 Japanese medical students (41 men, 19 women)
Duration
24 weeks
Results
CP2305 significantly reduced anxiety and sleep disturbance vs placebo. Shortened sleep latency, wake time after sleep onset, and increased delta power ratio. Attenuated stress-induced decline of Bifidobacterium spp. and stress-induced elevation of Streptococcus spp.
How They Measured It
Spielberger State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, polysomnography, salivary cortisol, gut microbiota analysis
Frequently Asked Questions
Common questions about Lactobacillus gasseri research
There are currently 10 peer-reviewed studies on Lactobacillus gasseri (Lactobacillus gasseri), involving 918 total participants. Research covers Weight management, Gut health, Metabolic health. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (9 human studies), and reported outcomes.
Lactobacillus gasseri has been researched for: Weight management, Gut health, Metabolic health. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 9 out of 10 studies are human trials. Human trials carry more weight in our evidence scoring system.
